ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about ImmunityBio, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | -1.872 | - | 0.85 | - | -952 | - | 0.85 | - | 0.85 | - | 156 |
| 2016 | -0.8280 | -1.620 | 0.24 | 0.09 | -236 | -823 | -235 | 0.09 | -238 | 0.09 | 227 | 16 |
| 2017 | -0.3680 | -1.220 | 0.04 | 0.04 | -120 | -620 | -117 | 0.04 | -124 | 0.04 | 95 | 7 |
| 2018 | -0.2990 | -1.318 | 0.05 | 0.04 | -96 | -670 | -90 | 0.04 | -99 | 0.04 | 57 | 8 |
| 2019 | -0.3000 | -0.740 | 0.05 | 0.10 | -96 | -376 | -86 | 0.10 | -98 | 0.10 | 42 | 18 |
| 2020 | -0.4200 | -0.770 | 2 | 0.11 | -160 | -391 | -139 | 0.11 | -165 | 0.11 | 46 | 19 |
| 2021 | -0.5900 | -1.350 | 0.61 | 0.57 | -224 | -686 | -195 | 0.57 | -219 | 0.57 | 71 | 104 |
| 2022 | -0.9000 | -1.000 | 0.93 | 0.19 | -349 | -508 | -316 | 0.19 | -330 | 0.19 | 135 | 35 |
| 2023 | -1.0400 | -0.930 | 0.24 | 0.51 | -417 | -478 | -343 | 0.51 | -374 | 0.51 | 102 | 93 |
| 2024 | -1.1500 | -0.820 | 0.62 | 10 | -583 | -417 | -342 | -10 | -361 | -10 | 129 | 1,866 |
| 2025 | - | -0.635 | - | 138 | - | -322 | - | -138 | - | -138 | - | 25,426 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |